Table 2.

Clinical trials of NR in COVID-19.

Treatment Regimen	Description	Type	Status	Clinical Trial
1 g of NR or placebo orally every morning for 14 days	to investigate whether NR supplementation can attenuate the severity of SARS-CoV-2 infections in elderly patients	randomized double-blinded case–control trial	Unknown	NCT04407390
250 mg NR capsules administered twice daily for 10 days	treatment with NR in COVID-19 patients for renal protection	prospective, double-blind, placebo-controlled clinical interventional trial	Active, not recruiting	NCT04818216
2000 mg NR in the form of capsules daily	to examine recovery in people with persistent cognitive and physical symptoms after COVID-19 illness	Double-blinded, randomized, parallel-group, placebo-controlled design	Recruiting	NCT04809974
hydroxychloroquine (standard therapy) + dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine, and NR	metabolic cofactor supplementation and hydroxychloroquine combination in COVID-19 patients	parallel-group, randomized, and open-label study	Recruiting	NCT04573153